symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
PROK,2.67,1.051162,472940,1746415048,0,2.37-14.19,-0.23,ProKidney Corp.,USD,0001850270,,,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.prokidney.com,"ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.","Dr. Timothy A. Bertram D.V.M., Ph.D.",Healthcare,US,87,336 999 7028,2000 Frontis Plaza Blvd.,Winston-Salem,NC,27103,,0,https://financialmodelingprep.com/image-stock/PROK.png,2021-06-30,False,False,True,False,False
